TECX — Tectonic Therapeutic, Inc. stock price, charts and financials

Latest market price

29.17

+1.25+4.48%

Overview Short InterestFilings

TECXQT62Tectonic Therapeutic, Inc.·NASDAQ

Overview Short InterestFilings

29.17+4.48%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

OCUL+2.26%$8.59 MESO+2.28%$14.80 AUPH+2.47%$14.93 TYRA+1.53%$32.53 URGN+3.45%$39.92 IOVA+0.93%$4.36 STOK+7.14%$31.67 TSHA+7.27%$6.20

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	40.70%	Shs Outstand	18.87M	Perf Week	-2.11%

Market Cap	550.41M	Forward P/E	-	EPS next Y	-5.68	Insider Trans	-0.14%	Shs Float	9.48M	Perf Month	-17.18%

Enterprise Value	316.41M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	20.43%	Perf Quarter	-1.62%

Income	-74.00M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	9.35	Perf Half Y	29.53%

Sales	0.00	P/B	2.39	EPS next Y	-6.43%	ROA	-33.86%	Short Interest	1.94M	Perf YTD	39.84%

Book/sh	12.19	P/C	2.32	EPS next 5Y	-	ROE	-32.33%	52W High	39.53 -26.21%	Perf Year	40.71%

Cash/sh	12.56	P/FCF	-	EPS past 3/5Y	-	ROIC	-39.58%	52W Low	14.39 102.71%	Perf 3Y	56.83%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	5.45% 5.78%	Perf 5Y	-66.14%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-13.49%	Oper. Margin	0.00%	ATR (14)	1.84	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	18.51	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	42.67	Recom	1.80

Dividend Gr. 3/5Y	-	Current Ratio	18.51	EPS Q/Q	-44.09%	SMA20	-7.53%	Beta	1.29	Target Price	78.00

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-6.12%	Rel Volume	0.75	Prev Close	27.92

Employees	60	LT Debt/Eq	0.01	Earnings	Aug 06	SMA200	14.15%	Avg Volume	195.61K	Price	29.17

IPO Date	Jun 21, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-15.01% -	Net Debt/EBITDA	2.88	Volume	145,906	Change	4.48%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-26-26	Upgrade	Raymond James	Outperform → Strong Buy	$81
Apr-13-26	Initiated	Stifel	Buy	$75
Jan-08-26	Reiterated	Truist Securities	Buy	$60

Company

Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018	FY 2017 12/31/2017
Total Revenue	0	0	0	0	0	0	0	0	0
Cost of Goods Sold Incl. D&A	0	0	0	0	0	1	1	0	0
Gross Profit	0	0	0	0	0	-1	-1	0	0
Selling, General and Administrative Excl. Other	21	17	8	7	5	33	20	11	3
Research and Development	63	41	37	26	11	86	55	35	15
Other Operating Expense	0	0	0	0	0	0	0	0	0
Operating Income	-84	-58	-45	-33	-16	-120	-76	-46	-18
Interest Expense	0	0	0	0	0	0	0	0	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	11	0	2	1	7	1	3	0	0
Net Income Before Taxes	-73	-58	-43	-32	-9	-120	-73	-46	-19
Income Taxes	1	0	0	0	0	0	0	0	0
Consolidated Net Income	-74	-58	-43	-32	-9	-120	-73	-46	-19
Net Income From Continuing Operations	-74	-58	-43	-32	-9	-120	-73	-46	-19
Net Income	-74	-58	-43	-32	-9	-120	-73	-46	-19
EPS (Recurring)	-4.05	-3.93	-11.59	-29.05	-33.36	-39.68	-31.92	-23.41	-9.35
EPS (Basic, Before Extraordinaries)	-4.05	-3.93	-11.59	-29.05	-33.36	-39.68	-31.92	-23.41	-9.35
EPS (Diluted)	-4.05	-3.93	-11.53	-29.05	-33.36	-39.68	-31.92	-23.41	-9.35
EBITDA	-71	-56	-41	-31	-8	-119	-72	-46	-19
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	18	15	4	4	4	3	2	2	2
Market Capitalization	375	693	65	34	185	502	483	400	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McNamara Peter	Chief Scientific Officer	Jun 30 '26	Sale	35.00	172	6,020	55,285	Jul 01
McNamara Peter	Chief Scientific Officer	Jun 30 '26	Option Exercise	14.71	172	2,530	55,457	Jul 01
Ruddy Marcella K.	Chief Medical Officer	May 04 '26	Sale	30.00	1,065	31,950	67,682	May 06
Ruddy Marcella K.	Chief Medical Officer	Apr 01 '26	Sale	31.05	1,000	31,050	68,747	Apr 03
McNamara Peter	Chief Scientific Officer	Mar 06 '26	Sale	30.17	6,262	188,935	55,285	Mar 09
Ruddy Marcella K.	Chief Medical Officer	Mar 06 '26	Sale	30.00	10,000	300,000	69,747	Mar 09
McNamara Peter	Chief Scientific Officer	Mar 06 '26	Option Exercise	3.36	2,715	9,113	61,547	Mar 09
McNamara Peter	Chief Scientific Officer	Mar 04 '26	Sale	25.00	1,650	41,250	58,832	Mar 05
McNamara Peter	Chief Scientific Officer	Mar 03 '26	Sale	22.06	1,649	36,377	37,482	Mar 05
REICIN ALISE	Chief Executive Officer	Feb 11 '26	Buy	21.10	5,000	105,500	237,547	Mar 05
Schwabish Marc	Chief Business Officer	Feb 10 '26	Option Exercise	2.38	4,500	10,710	25,814	Feb 12
Lochner Daniel	Chief Financial Officer	Feb 10 '26	Buy	21.61	6,000	129,660	32,044	Feb 11
REICIN ALISE	Chief Executive Officer	Dec 31 '25	Option Exercise	2.38	10,966	26,099	239,151	Jan 05
McNamara Peter	Chief Scientific Officer	Dec 22 '25	Option Exercise	2.98	7,000	20,860	40,879	Dec 29
SPRINGER TIMOTHY A	director, 10 percent owner:	Apr 11 '25	Buy	16.31	63,184	1,030,531	4,334,846	Apr 11

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.